Apr 18 |
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
|
Apr 12 |
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
|
Apr 11 |
NeuroSense Therapeutics sheds 6% on $4.5M direct private offering
|
Apr 10 |
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
|
Apr 9 |
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
|
Apr 8 |
NeuroSense Therapeutics GAAP EPS of -$0.83 misses by $0.01
|
Apr 5 |
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
|
Feb 21 |
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
|
Feb 7 |
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
|
Jan 30 |
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
|